RecruitingPriority 4 · Lower priorityNCT04014374
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Plain-language summary
This trial is testing a new treatment for people whose adult T-cell leukemia/lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
- Drugs / treatments
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details